The CHMP positive opinion is based on the EFFISAYIL® 2 trial, which showed that no flares were observed after week 4 of SPEVIGO® administered subcutaneously. During the 48-week trial, an 84% red......
VANCOUVER, British Columbia, July 29, 2024 (GLOBE NEWSWIRE) -- Bedford Metals Corp. (TSX-V: BFM, FWB: O8D, ISIN: CA0762301012) (the “Company” or “Bedford”) is pleased to announce that it has rec......
Group sales amounted to EUR 4.5 billion, with comparable sales growth of 2%
Comparable order intake increased by 9%
Income from operations EUR 816 mill......
